Why Synthetic Cannabinoids Are Not the Same as Cannabis

For years, headlines about “synthetic cannabis” have fueled confusion among consumers, policymakers, and even healthcare providers. Reports of seizures, psychosis, cardiovascular emergencies, and overdoses are often associated with synthetic cannabinoids, yet many people mistakenly assume those risks apply equally to natural cannabis.

A 2026 study¹ suggests that the assumption oversimplifies a much more complex issue. A recent policy viewpoint examining novel psychoactive substances (NPS) argues that while certain synthetic cannabinoids clearly warrant strong public health protections, drug policy should also leave room for carefully controlled scientific research. Rather than treating every emerging substance as identical, the authors propose a more evidence-based framework that distinguishes between compounds according to their actual risks and potential medical value.

The message is especially important for cannabis consumers. Plant-derived cannabis and synthetic cannabinoids are fundamentally different substances, and understanding those differences can help improve both public health and future research. Let’s dive into the study and exactly what synthetic cannabinoids are.

Synthetic Cannabinoids Are Not Cannabis

Despite their name, synthetic cannabinoids are not simply laboratory-made versions of cannabis. Most synthetic cannabinoids are chemically manufactured compounds designed to interact with the body’s cannabinoid receptors while avoiding existing drug laws. They have often been sold under misleading names such as “legal highs,” “research chemicals,” or products marketed as synthetic cannabis.

While these substances may activate some of the same biological pathways as cannabis, they behave very differently inside the body. The research explains that the primary intoxicating compound in cannabis, delta-9-tetrahydrocannabinol (THC), functions primarily as a partial agonist at CB1 cannabinoid receptors. Many synthetic cannabinoids, by contrast, act as full CB1 agonists and may bind to these receptors with up to 100 times greater affinity than THC. That difference is not simply technical; it can dramatically affect safety.

Why Synthetic Cannabinoids Can Be More Dangerous

The strong receptor activity of many synthetic cannabinoids helps explain why they have been linked to disproportionately severe health effects. Emergency department reports and clinical research have associated certain synthetic cannabinoids with seizures, rapid heart rate, high blood pressure, loss of consciousness, severe confusion, psychosis, memory impairment, and other serious neurological and cardiovascular complications.

Controlled human studies cited in the paper found that one early synthetic cannabinoid, JWH-018, produced much stronger psychotomimetic effects than cannabis at comparable psychoactive doses. Participants experienced symptoms including derealization, depersonalization, confusion, and amnesia.

Researchers also noted considerable variability in how individuals absorbed these compounds, making dosing unpredictable and increasing overdose risk. These findings reinforce an important point that synthetic cannabinoids should not be used as evidence that cannabis itself produces the same level of risk.

A Growing Challenge for Drug Policy

Synthetic cannabinoids are only one category within a much larger group known as novel psychoactive substances. According to the study, more than 1,400 different NPS have been detected internationally since 2009. Many are designed specifically to mimic existing illicit drugs while remaining temporarily outside international drug control laws.

Due to new compounds appearing rapidly, governments often respond by placing them into the most restrictive legal classifications. While that approach may reduce public availability, the researchers argue it can also create an unintended consequence as the same regulations intended to protect public health may make it far more difficult for scientists to study these substances under carefully controlled conditions. Without high-quality clinical research, policymakers may have limited evidence about actual risks, abuse potential, or possible therapeutic applications.

Research Should Not Be Confused With Approval

One of the paper’s central arguments is that allowing tightly regulated scientific research does not mean endorsing recreational use. The authors emphasize that compounds can remain heavily controlled while still being accessible to licensed researchers conducting approved laboratory and clinical studies. This distinction matters because history has shown that some substances initially viewed only as dangerous have later demonstrated legitimate medical value after rigorous investigation.

• Institutional Licensing Hurdles: Academic and medical institutions face heavy administrative challenges when trying to secure the specialized government licenses required to legally handle highly restricted substances.
• Lack of First-in-Human Safety Data: Institutional Review Boards (IRBs) are frequently hesitant to approve first-in-human clinical trials without extensive, expensive preclinical safety data.
• Import and Export Barriers: The complex regulatory framework governing the cross-border shipping of controlled substances introduces massive delays and logistical bottlenecks for international research collaborations.
• High Cost of Pharmaceutical-Grade Compounds: Securing high-purity chemical formulations that meet mandatory Good Manufacturing Practice (GMP) standards for human clinical trials requires immense funding that independent researchers rarely have.

The paper highlights several examples, including psychedelics that are being studied for depression and anxiety, as well as MDMA-assisted psychotherapy for post-traumatic stress disorder. It also discusses certain synthetic cathinones, where research has contributed to approved medications or promising clinical investigations.

The authors argue that similar evidence-based evaluation should be possible for novel psychoactive substances rather than assuming every new compound belongs permanently in the highest legal category.

A Four-Step Research Framework

Instead of relying on immediate permanent prohibition, the researchers propose a four-stage framework for evaluating emerging psychoactive substances.

The process begins with early surveillance to identify new compounds and monitor signs of harm using toxicology reports, wastewater surveillance, emergency department data, and drug-checking programs. If concerns emerge, a provisional scheduling stage would temporarily control public access while still permitting licensed scientific research. Researchers could then conduct controlled studies examining pharmacology, safety, abuse liability, cognitive effects, psychiatric outcomes, and possible therapeutic uses.

Finally, regulators could reclassify the substance using the combined evidence gathered from laboratory research, toxicology, clinical findings, and public health surveillance. The goal is to make drug policy more adaptive as scientific knowledge evolves rather than relying solely on assumptions made when little evidence exists.

Cannabis Policy Offers an Important Lesson

For cannabis consumers, perhaps the biggest takeaway is the importance of avoiding overly broad comparisons. Natural cannabis, synthetic cannabinoids, and other novel psychoactive substances represent distinct categories with different chemical structures, pharmacology, and safety profiles. Treating every cannabinoid-related substance as though it carries identical risks can create confusion for consumers while making meaningful public health education more difficult.

At the same time, the paper does not argue that every novel psychoactive substance is safe or deserves widespread availability. It is actually quite the opposite. The authors acknowledge that some synthetic cannabinoids clearly pose substantial risks and support strong public health protections where evidence demonstrates significant harm. Their argument is instead that regulation should remain flexible enough to allow high-quality scientific investigation alongside appropriate public safeguards.

Better Evidence Supports Better Decisions

Drug policy is often forced to keep pace with a constantly changing marketplace of new psychoactive substances. As synthetic cannabinoids continue to emerge, distinguishing them from plant-derived cannabis becomes increasingly important for both public understanding and scientific accuracy.

The recent policy viewpoint suggests that protecting public health and advancing research do not have to be competing goals. Strong regulation can coexist with carefully controlled scientific access, allowing researchers to better understand which substances present unacceptable risks, which offer no meaningful benefit, and which may eventually prove useful in medicine.

For cannabis advocates, healthcare professionals, and policymakers alike, the lesson is clear: drug policy works best when it distinguishes between plant-derived cannabis, synthetic cannabinoids, and other emerging psychoactive substances rather than treating them as a single risk category. Each group has unique pharmacology, safety profiles, and potential therapeutic applications that deserve independent scientific evaluation. As the authors argue, evidence-based regulation is strongest when it reflects those differences instead of assuming all psychoactive substances carry the same risks or benefits.

References:

^{1. Ramaekers JG, Bade R, Hall W, How can we facilitate research on the risks and potential benefits of novel psychoactive substances?, eClinicalMedicine, Volume 97, 2026, 104030, ISSN 2589-5370, https://doi.org/10.1016/j.eclinm.2026.104030}